Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Research led by Carlo Rinaldi and Catheryn Lim discovered that a naturally-occurring isoform of an androgen receptor can be used in therapy for spinal and bulbar muscular atrophy, and shows potential for other diseases.

Lab mouse

A study published in Science Advances shows very promising results for gene therapy treatment of neuromuscular conditions - and beyond.

Carlo Rinaldi, who led the research, explains:

"By performing deep transcriptomic analysis of human tissues, we have identified several naturally-occurring isoforms of the transcription factor Androgen Receptor (AR). One of these, AR isoform 2, attracted our interest because it is the most highly expressed, particularly in AR-responsive cell populations, such as motor neurons and skeletal muscle. Intriguingly, we found that this isoform, which encodes a truncated AR 45 kilodaltons in size (hence the name AR45), plays a fundamental role in biology by acting as a transcriptional decoy, fine-tuning AR activity by competitively occupying its DNA binding sites. Capitalising on this new knowledge, we delivered AR45 via recombinant adeno-associated virus (AAV) to a mouse model of spinal and bulbar muscular atrophy (SBMA), a genetic neuromuscular disease with high unmet clinical need, caused by mutations in AR by a mechanism of toxic gain-of-function. This strategy restored the altered transcriptional profile in affected tissues and strongly ameliorated the disease phenotype in mice, laying the ground for an innovative gene therapy approach."

Given the critical importance of AR transcriptional control in various diseases such as androgen insensitivity syndrome, benign prostatic hyperplasia, and prostate cancer, this isoform may potentially be a target for therapy not only for SBMA but also for other AR-related conditions.

Work currently underway in many laboratories to fully understand AAV biology and develop methods for improved delivery and manufacturing for human studies, will be absolutely critical to translate this and other promising gene therapy approaches into treatments for patients.

Lim, Wooi F., et al. "Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype 2 by modulating AR transcriptional activity: AR isoform 2 counteracts polyglutamine AR toxicity." Science Advances (2021): abi6896. DOI: 10.1126/sciadv.abi6896

Similar stories

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the two NIHR Biomedical Research Centres.

Study raises hope of pre-school type 1 diabetes screening programme

Researchers in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes before children develop symptoms or need insulin.

AR cooperates with SMAD4 to maintain skeletal muscle homeostasis

Skeletal muscle, which accounts for over 40% of the total mass in healthy individuals, plays a central role in maintenance of organismal homeostasis. Conversely, muscle atrophy upon acute and chronic conditions, ranging from genetic muscular dystrophy to critical illnesses, cachexia and sarcopenia, significantly correlates with levels of disability and is an important predictor of mortality. Despite the urgent medical need, treatments able to efficiently counteract muscle loss are lacking due to an incomplete understanding of the underlying intricate molecular mechanisms of regulation.

Angelman syndrome: first patient to receive potential therapy in Oxford

Things that seemed impossible, only a few years ago, are happening today. The first patient in Europe and one of the first in the world was injected with a potential treatment, GTX-102, in a phase I/II clinical trial in Oxford.

New model for infant leukaemia announced

The breakthrough could lead to development of new treatments for infant Acute Lymphoblastic Leukaemia.